CSL Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Millions.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,424
1,656
1,707
1,773
2,231
Depreciation, Depletion & Amortization
212
218
303
370
383
Other Funds
7
8
230
28
38
Funds from Operations
1,586
1,946
1,762
2,024
2,817
Changes in Working Capital
104
309
143
371
363
Net Operating Cash Flow
1,482
1,637
1,620
1,653
2,455
Capital Expenditures
438
497
777
1,141
1,281
Sale of Fixed Assets & Businesses
-
-
-
-
-
Purchase/Sale of Investments
-
-
-
3
2
Net Investing Cash Flow
437
496
1,113
1,144
1,980
Cash Dividends Paid - Total
568
643
796
797
868
Issuance/Reduction of Debt, Net
214
590
1,165
-
-
Net Financing Cash Flow
1,239
994
498
137
479
Net Change in Cash
167
61
-
381
39
Free Cash Flow
1,097
1,220
939
739
1,450
Deferred Taxes & Investment Tax Credit
56
65
17
147
165
Net Assets from Acquisitions
-
-
336
-
697
Change in Capital Stock
885
941
867
401
158
Exchange Rate Effect
27
208
9
10
35

About CSL

View Profile
Address
45 Poplar Road
Parkville Victoria (VIC) 3052
Australia
Employees -
Website http://www.csl.com.au
Updated 07/08/2019
CSL Ltd. is a biopharmaceutical company, which engages in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma.